This notice is an invitation for you to take part in a psychedelic research study from the University of Wisconsin-Madison. The study focuses on the context of psychedelic administration in scientific and clinical research. Participation in all aspects of this study is entirely voluntary. Even if you begin part of the study, but then change your mind about further participation, you may opt out at any time.
You will not receive any direct benefit from completion of this study. We do expect that others may benefit from your participation in this study, as it will help improve future studies that use psychedelic compounds, including studies in populations that are underrepresented in current data sets.
The link at the bottom of this invitation will take you to an initial screening form, which is expected to take about 2-3 minutes to complete. After the screening form has been completed, you may be contacted by the investigators with an invitation to participate in an online survey, a focus group, or both.
Everyone completing the screening form will be invited to participate in a 60-minute debriefing session, even if they are not selected to participate in the online survey or the focus group. In this session, we will discuss the goals and purpose of the study as well as some of our findings to date. An email invitation to this session will be sent after the survey and focus groups are completed.
If you are invited to complete the online survey, it is expected to take about 30-45 minutes to complete. The online survey is composed of several shorter sections, with opportunities to save and take a break provided between sections. If you are selected to complete the survey, information on how to access and complete it will be included in a follow-up email.
If you are invited to join a focus group by video conference, it is expected to last for 60 - 90 minutes. The focus group session will gather personal opinions on mental illness, drug research studies, and psychedelic therapy. Focus groups will consist of verbal free responses to questions within a small group setting. Focus group sessions will be audio recorded. We won’t ask for identifying information, but any identifying information mentioned will be removed from the recording to preserve anonymity. If you are selected to participate in the focus group, information on how to sign up for and attend the meeting will be included in a follow-up email.
If you are selected to participate in the survey and focus group, the maximum total time commitment is expected to be between 3 and 4 hours.
If you are selected for participation in the online survey, the focus group, or both, there are potential risks to you and your reputation in the event of a confidentiality breach. To address these risks, an email address is the only personally identifying information that will be collected. This email address will be used only for sending follow-up invitations to the online survey, the focus group, and/or the debriefing session.
Email addresses will not be shared with anyone or any group outside of the study team, and will be deleted from the database following completion of the debriefing session. All data will be stored on a secure database with access limited to study team members only.
Thank you very much for taking the time to consider this information. If you think you may be interested in participating in this study, please click the link shown below to proceed to the screening form.
Learn more at the POIESIS Study Information Session
Dr. Cody Wenthur is an innovative, translational investigator in psychopharmacology who has been on the UW–Madison faculty since 2018. His work is focused on improving our understanding of the basis for beneficial and detrimental effects of opioids, cannabinoids, psychedelics, and other neuroplasticity-inducing approaches in the context of novel therapeutic approaches for promoting and maintaining mental health.
His research program has received both basic and clinical grant and fellowship support from NIGMS, NIDA, NIMH, independent foundations, and philanthropic funds. The resulting findings have been published in leading journals such as Nature and PNAS and have yielded the development of first-in-class tool compounds and generated new pharmacologic techniques for the investigation of complex psychoactive mixtures.
His scientific research is complemented by his dedicated support of graduate education in neuropharmacology, including active service as the founding director of the Psychedelic Pharmaceutical Investigation Master’s program, and mentorship of PharmD and PhD students in the Pharmaceutical Sciences, Molecular and Cellular Pharmacology, and Neuroscience Training Programs.